These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 7689654

  • 1. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.
    Saltz L, Sirott M, Young C, Tong W, Niedzwiecki D, Tzy-Jyun Y, Tao Y, Trochanowski B, Wright P, Barbosa K.
    J Natl Cancer Inst; 1993 Sep 15; 85(18):1499-507. PubMed ID: 7689654
    [Abstract] [Full Text] [Related]

  • 2. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
    Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC.
    J Clin Oncol; 1996 Apr 15; 14(4):1224-35. PubMed ID: 8648378
    [Abstract] [Full Text] [Related]

  • 3. Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
    Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL.
    J Clin Oncol; 1994 Dec 15; 12(12):2743-50. PubMed ID: 7527456
    [Abstract] [Full Text] [Related]

  • 4. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor.
    Abbruzzese JL, Madden T, Sugarman SM, Ellis AL, Loughlin S, Hess KR, Newman RA, Zwelling LA, Raber MN.
    Clin Cancer Res; 1996 Sep 15; 2(9):1489-97. PubMed ID: 9816325
    [Abstract] [Full Text] [Related]

  • 5. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G, Briasoulis E, Karavassilis V, Mauri D, Tzamakou E, Rammou D, Pavlidis N.
    Chemotherapy; 2005 May 15; 51(2-3):154-61. PubMed ID: 15886476
    [Abstract] [Full Text] [Related]

  • 6. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer.
    Murren JR, Anderson S, Fedele J, Pizzorno G, Belliveau D, Zelterman D, Burtness BA, Tocino I, Flynn SD, Beidler D, Cheng YC.
    J Clin Oncol; 1997 Jan 15; 15(1):148-57. PubMed ID: 8996136
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
    Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL.
    J Clin Oncol; 1995 Sep 15; 13(9):2230-7. PubMed ID: 7545219
    [Abstract] [Full Text] [Related]

  • 8. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer.
    Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T.
    J Clin Oncol; 1994 Sep 15; 12(9):1833-41. PubMed ID: 7521905
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
    Schiller JH, Kim K, Hutson P, DeVore R, Glick J, Stewart J, Johnson D.
    J Clin Oncol; 1996 Aug 15; 14(8):2345-52. PubMed ID: 8708727
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
    Tolcher AW, O'Shaughnessy JA, Weiss RB, Zujewski J, Myhand RC, Schneider E, Hakim F, Gress R, Goldspiel B, Noone MH, Brewster LR, Gossard MR, Cowan KH.
    Clin Cancer Res; 1997 May 15; 3(5):755-60. PubMed ID: 9815746
    [Abstract] [Full Text] [Related]

  • 11. Phase I study of topotecan for pediatric patients with malignant solid tumors.
    Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT.
    J Clin Oncol; 1994 Mar 15; 12(3):539-43. PubMed ID: 8120551
    [Abstract] [Full Text] [Related]

  • 12. Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
    Creemers GJ, Gerrits CJ, Eckardt JR, Schellens JH, Burris HA, Planting AS, Rodriguez GI, Loos WJ, Hudson I, Broom C, Verweij J, Von Hoff DD.
    J Clin Oncol; 1997 Mar 15; 15(3):1087-93. PubMed ID: 9060549
    [Abstract] [Full Text] [Related]

  • 13. High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study.
    Rowinsky EK, Baker SD, Burks K, O'Reilly S, Donehower RC, Grochow LB.
    Ann Oncol; 1998 Feb 15; 9(2):173-80. PubMed ID: 9553662
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    O'Reilly S, Fleming GF, Barker SD, Walczak JR, Bookman MA, McGuire WP, Schilder RJ, Alvarez RD, Armstrong DK, Horowitz IR, Ozols RF, Rowinsky EK.
    J Clin Oncol; 1997 Jan 15; 15(1):177-86. PubMed ID: 8996140
    [Abstract] [Full Text] [Related]

  • 15. Camptothecin analogues: studies from the Johns Hopkins Oncology Center.
    Slichenmyer WJ, Rowinsky EK, Grochow LB, Kaufmann SH, Donehower RC.
    Cancer Chemother Pharmacol; 1994 Jan 15; 34 Suppl():S53-7. PubMed ID: 7520844
    [Abstract] [Full Text] [Related]

  • 16. Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
    Rowinsky EK, Kaufmann SH, Baker SD, Grochow LB, Chen TL, Peereboom D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA, Donehower RC.
    J Clin Oncol; 1996 Dec 15; 14(12):3074-84. PubMed ID: 8955652
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical trial of weekly combined topotecan and irinotecan.
    Lokich J.
    Am J Clin Oncol; 2001 Aug 15; 24(4):336-40. PubMed ID: 11474256
    [Abstract] [Full Text] [Related]

  • 18. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
    Saltz L, Janik JE.
    Semin Oncol; 1997 Feb 15; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
    [Abstract] [Full Text] [Related]

  • 19. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer.
    Hainsworth JD, Burris HA, Morrissey LH, Greco FA.
    Cancer; 1999 Mar 01; 85(5):1179-85. PubMed ID: 10091804
    [Abstract] [Full Text] [Related]

  • 20. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ, Burris H, Schellens JH, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Fields S, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1998 May 01; 4(5):1153-8. PubMed ID: 9607572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.